289-95-2
289-95-2
Chemical Structure
Pyrimidine
- CAS No.: 289-95-2
- Formula:C4H4N2
- Molecular Weight:80.09
IUPAC Name: pyrimidine
InChIKey: CZPWVGJYEJSRLH-UHFFFAOYSA-N
SMILES: C1=NC=CC=N1
Biological Activity: Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pyrimidine | 99.99% | Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pyrimidine (Standard) | 98.75% | Pyrimidine (Standard) is the analytical standard of Pyrimidine. This product is intended for research and analytical applications. Pyrimidine is a nitrogen-containing heterocyclic compound and endogenous metabolite. Pyrimidine derivatives can be used in pancreatic cancer, triple-negative breast cancer, colon carcinoma and neuron research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Halbrook CJ, et al. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Cell Metab. 2019 Jun 4;29(6):1390-1399.e6. [Content Brief]
- [2]. Inoue K. Microglial activation by purines and pyrimidines. Glia. 2002 Nov;40(2):156-163. [Content Brief]
- [3]. Taglieri L, et al. Discovery of a pyrimidine compound endowed with antitumor activity. Invest New Drugs. 2020 Feb;38(1):39-49. [Content Brief]
Keywords
